Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
Early Detection of Prostate Cancer: AUA/SUO Guideline (2026)
Using AUA Guidelines
Access to AUA guidelines is provided free for individuals’ clinical use only. Anyone accessing AUA guidelines for any other purpose must obtain a license in advance. Licenses for academic, research and educational purposes can be requested through the AUA by contacting permissions@AUAnet.org.
Licenses for promotional or commercial use can be requested by contacting Keith Price at kprice@AUAnet.org.
Access FAQs on AUA clinical guideline usage and licensing.
By reading this guideline, you agree to AUA's Guidelines Terms and Conditions of Use.
Using AUA Guidelines
Access to, and limited authorized use of AUA guidelines is a member benefit. Members are granted a limited license to access and use the AUA Guidelines for their individual, non-commercial use, for clinical, academic, educational, and research purposes, in accordance with the AUA Guidelines Terms and Conditions of Use. Members who wish to use the Guidelines for any other purpose, or in any manner not authorized by this limited license grant or by the AUA Guidelines Terms and Conditions of Use must request and obtain a license/permission in advance. Licenses for business or institutional academic, research and educational related purposes (e.g., use in course packs or for employer-sponsored research) can be requested through the AUA by contacting permissions@AUAnet.org.
Licenses for promotional or commercial use can be requested by contacting Keith Price at kprice@AUAnet.org.
Access FAQs on AUA clinical guideline usage and licensing.
By reading this guideline, you agree to AUA's Guidelines Terms and Conditions of Use.
Using AUA Guidelines
Access to AUA guidelines is provided free for individual clinical use only, in accordance with the AUA Guidelines Terms and Conditions of Use. Anyone accessing AUA guidelines for any other purpose must obtain a license/permission in advance. Licenses for academic, research and educational purposes (e.g., in course packs or employer-sponsored research) can be requested through the AUA by contacting permissions@AUAnet.org.
Licenses for promotional or commercial use can be requested by contacting Keith Price at kprice@AUAnet.org.
Access FAQs on AUA clinical guideline usage and licensing.
By reading this guideline, you agree to AUA's Guidelines Terms and Conditions of Use.
Using AUA Guidelines
Access to AUA guidelines is provided free for health care providers for their individual clinical use only. Patients and the general public are provided a summary of the guidelines. Patients who wish to discuss the full guidelines should consult with their healthcare provider.
Guideline Resources
Unabridged PDF for this Guideline
Amendment Summary for this Guideline
Algorithm for this Guideline
The Journal of Urology® Articles
Published 2023; Amended 2026
Purpose
This Guideline provides recommendations for prostate cancer screening in different groups based on their age range and risk criteria, with an emphasis on shared decision-making. Clinicians may tailor the definitions of elevated risk and elevated PSA to the clinical situation at hand. This Guideline emphasizes potential benefit in using validated risk calculators and provides recommendations for the timing and methodology for screening.
Key Takeaways
The recommendations discussed on the early detection of prostate cancer provide a framework to facilitate clinical decision-making in the implementation of prostate cancer screening and follow-up:
- PSA screening
- Initial biopsy
- Repeat biopsy
- Biopsy technique
This Guideline underscores the goal of detecting “clinically significant” cancer for initial and repeat biopsy. This Guideline defines clinically significant prostate cancer as GG2 or higher (GG2+) prostate cancer and will use “clinically significant prostate cancer” and “GG2+” interchangeably throughout. The Guideline also addresses the significance of non-cancerous, yet potentially significant, pathologic findings identified from the biopsy.
Create a free account to access expanded content and resources.
AUA Clinical Practice Guidelines are developed by multidisciplinary panels of experts based on rigorous systematic review of current urologic research.
| Free Resources | |
 |
Prostate Cancer Patient Resources |
|
Urology A-Z Early-Stage Prostate Cancer Web Article |
| Login to Continue | |
| Member Benefit | |
|
Unabridged PDF for this Guideline |
|
Amendment Summary for this Guideline |
|
Algorithm for this Guideline |
|
The Journal of Urology® Articles |